Glomerular disease: The search goes on: suPAR is not the elusive FSGS factor.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

8 citing papers in PubMed.

1. Podocyte-targeted therapies - progress and future directions.Nature reviews. Nephrology · 2024
   Review
2. Serum C3 and Renal Outcome in Patients with Primary Focal Segmental Glomerulosclerosis.Scientific reports · 2017
   Article
3. Patients With Combined Membranous Nephropathy and Focal Segmental Glomerulosclerosis Have Comparable Clinical and Autoantibody Profiles With Primary Membranous Nephropathy: A Retrospective Observational Study.Medicine · 2016
   Observational
4. The glomerular permeability factors in idiopathic nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2016
   Review
5. Plasma Soluble Urokinase Receptor Level Is Correlated with Podocytes Damage in Patients with IgA Nephropathy.PloS one · 2015
   Article
6. Soluble Urokinase Receptor Levels Are Correlated with Focal Segmental Glomerulosclerosis Lesions in IgA Nephropathy: A Cohort Study from China.PloS one · 2015
   Article
7. Reply: Measurement of serum suPAR is not ready for clinical use.Nature reviews. Nephrology · 2014
   Article
8. suPAR is the circulating factor in some but not all FSGS.Nature reviews. Nephrology · 2014
   Article

Corrections and comments

• Commented on by
  suPAR is the circulating factor in some but not all FSGS.2014
• Commented on by
  Reply: Measurement of serum suPAR is not ready for clinical use.2014
• Comment on
  Administration of recombinant soluble urokinase receptor per se is not sufficient to induce podocyte alterations and proteinuria in mice.2014

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as